Orgenesis Inc (NASDAQ:ORGS), a developer of
advanced cell therapies, has struck a deal with Columbia University
under which it will fund research to develop a cellular vaccination
product platform.
Columbia University has created a patented dual-vaccine - focusing
on pancreatic, liver and bile duct cancers - that uses whole cancer
cells as a source of antigens and the patient's own immune
cells.
Under the terms of the research pact, Orgenesis will receive an
exclusive license on the technology developed at Columbia.
For article click here: https://bit.ly/2IAUdja
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.